세자리증후군(SS) : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2025-2035년)

Sezary Syndrome (SS) Market Outlook

Thelansis's "Sezary Syndrome (SS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sezary Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Sezary Syndrome (SS) Overview

Sezary syndrome (SS) is the rare leukemic variant of cutaneous T-cell lymphoma, characterized by malignant T cells circulating in the blood alongside widespread skin involvement, severe itching, and a more aggressive course than most other cutaneous T-cell lymphomas. Although therapies such as the CCR4-targeted antibody mogamulizumab have improved outcomes, relapse remains common, highlighting the need for new treatment options. This has driven interest in lacutamab, a first-in-class antibody targeting KIR3DL2, a receptor expressed on most Sezary syndrome cells, which has demonstrated promising activity in patients whose disease progressed after standard therapy. Development was temporarily paused because of a significant safety concern, but clinical evaluation has since resumed, with ongoing registrational studies assessing its role. For stakeholders, Sezary syndrome illustrates how rare-disease innovation can recover from meaningful clinical and regulatory setbacks.

Key Highlights

• In Germany, incident Sezary Syndrome (SS) cases are projected to remain stable at 45 cases between 2025 and 2035.
• Sezary Syndrome is a rare and aggressive leukemic variant of cutaneous T-cell lymphoma with poor prognosis.
• Patients often experience advanced disease, immune dysfunction, and limited treatment options.
• Significant unmet need remains for therapies that provide durable responses and improve survival.

Market Overview

• The Italy Sezary Syndrome market is projected to grow from $16M in 2025 to $38M by 2035.
• Market growth is driven by:
• Increasing adoption of targeted and immunotherapy-based treatments
• Ongoing development of novel therapies for cutaneous T-cell lymphoma
• Future growth will depend on therapies offering durable disease control and improved patient outcomes.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Innate Pharma
• SciTech Development, Inc.
• Prescient Therapeutics, Ltd.
• Kyowa Kirin, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)